Bristol Hospital Incorporated

Bristol Hospital Incorporated was paid $67.98M by Medicaid between Jan 2018 and Dec 2024, across 430 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.

33Billing provider infoBRISTOL HOSPITAL INCORPORATED
BRISTOL, CT 06011

33aNPI1619901642assigned 07/10/2006

33bProvider typeGeneral Acute Care Hospital

28Total paid$67.98M

24GClaims2,132,541

24DCodes billed430

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other General Acute Care Hospital providers in Connecticut

Rank by total paid#7 of 18

Median peer was paid$15.60M

This provider vs. median4.4×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	306,129	$9.42M
2019	305,068	$9.80M
2020	276,497	$8.07M
2021	311,316	$10.16M
2022	332,215	$10.63M
2023	334,202	$10.87M
2024incomplete	267,114	$9.03M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99284	Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity	18%	46,966	35,780	$12.04M
99283	Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity	15%	56,769	46,657	$10.43M
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	5.4%	29,251	22,331	$3.67M
99285	Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life	5.2%	7,622	6,054	$3.57M
97010		3.8%	41,716	10,248	$2.58M
G0463	Hospital outpatient clinic visit for assessment and management of a patient	3.0%	30,131	19,587	$2.05M
97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	2.7%	74,207	17,340	$1.84M
74177	Computed tomography, abdomen and pelvis; with contrast material	2.6%	9,970	8,166	$1.73M
99291	Critical care, evaluation and management of the critically ill patient, first 30-74 minutes	2.3%	2,819	2,241	$1.57M
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	1.8%	2,513	2,244	$1.20M
96361	Intravenous infusion, hydration; each additional hour	1.5%	24,781	17,387	$1.02M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	1.5%	17,309	14,420	$999K

418 more codes

99282	Emergency department visit for the evaluation and management, low to moderate severity	1.5%	8,856	$995K
S9480	Intensive outpatient psychiatric services, per diem	1.4%	9,140	$945K
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	1.3%	8,848	$904K
59025	Fetal non-stress test	1.3%	8,783	$892K
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	1.2%	7,070	$811K
96375	Therapeutic injection; each additional sequential IV push	1.2%	21,783	$792K
78452	Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress	1.1%	1,645	$722K
71046	Radiologic examination, chest; 2 views	<1%	12,527	$659K
93306	Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete	<1%	2,615	$619K
74176	Computed tomography, abdomen and pelvis; without contrast material	<1%	4,655	$598K
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	<1%	3,113	$582K
71045	Radiologic examination, chest; single view	<1%	12,358	$568K
93975		<1%	2,781	$532K
99213	Doctor's office visit, returning patient (routine)	<1%	13,216	$498K
77067	Screening mammography, bilateral, including computer-aided detection	<1%	4,295	$470K
95810	Polysomnography; sleep staging with 4 or more additional parameters	<1%	651	$466K
70450	Computed tomography, head or brain; without contrast material	<1%	9,220	$456K
97161		<1%	7,211	$407K
90853	Group psychotherapy (other than of a multiple-family group)	<1%	33,608	$407K
72125	Computed tomography, cervical spine; without contrast material	<1%	3,323	$372K
90832	Psychotherapy session, about 30 minutes	<1%	11,235	$354K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	12,253	$333K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	12,250	$332K
97597		<1%	4,033	$319K
90791	Psychiatric diagnostic evaluation	<1%	3,121	$300K
76705	Ultrasound, abdominal, real time with image documentation; limited	<1%	3,839	$299K
86900		<1%	8,555	$296K
71260	Computed tomography, thorax, diagnostic; with contrast material	<1%	2,146	$290K
45385	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s)	<1%	468	$263K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	14,026	$257K
84443	Thyroid stimulating hormone (TSH)	<1%	26,419	$252K
C8929	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography	<1%	899	$244K
97035		<1%	9,605	$242K
71275	Computed tomographic angiography, chest, with contrast material	<1%	2,296	$231K
70551	Magnetic resonance imaging, brain; without contrast material	<1%	1,780	$228K
76801		<1%	2,559	$220K
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete	<1%	2,454	$219K
80053	Comprehensive metabolic panel	<1%	71,601	$212K
H0015	Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education	<1%	1,749	$211K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	11,076	$211K
94060		<1%	1,464	$207K
80061	Lipid panel	<1%	23,396	$201K
45380	Colonoscopy, flexible; with biopsy, single or multiple	<1%	304	$201K
76830	Ultrasound, transvaginal	<1%	1,933	$188K
72148	Magnetic resonance imaging, lumbar spine; without contrast material	<1%	1,189	$182K
90834	Psychotherapy session, about 45 minutes	<1%	3,961	$171K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	5,442	$170K
97140	Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage)	<1%	58,478	$169K
73721	Magnetic resonance imaging, any joint of lower extremity; without contrast material	<1%	906	$163K
76641		<1%	1,955	$162K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	102,258	$161K
91065		<1%	1,442	$151K
93971		<1%	2,528	$147K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	2,470	$129K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	4,597	$125K
Q0138	Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)	<1%	830	$121K
62323		<1%	281	$121K
11042	Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm	<1%	819	$117K
83036	Hemoglobin; glycosylated (A1C)	<1%	19,757	$115K
76775		<1%	2,467	$106K
36415	Collection of venous blood by venipuncture	<1%	142,807	$101K
76816	Ultrasound, pregnant uterus, real time with image documentation, follow-up	<1%	1,184	$99K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	11,339	$98K
88142		<1%	7,582	$98K
99281	Emergency department visit for the evaluation and management, self-limited or minor	<1%	1,765	$96K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	8,512	$95K
97162		<1%	3,443	$94K
71250		<1%	1,747	$91K
76805	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation	<1%	837	$84K
82607		<1%	11,269	$84K
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	3,689	$82K
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	15,240	$78K
87800		<1%	2,268	$77K
93017		<1%	2,271	$76K
97602		<1%	1,098	$73K
94010		<1%	1,197	$67K
10060		<1%	496	$67K
77063	Screening digital breast tomosynthesis, bilateral	<1%	4,288	$63K
96367		<1%	1,796	$62K
88342		<1%	3,609	$61K
82728		<1%	9,816	$60K
20610		<1%	434	$57K
71271		<1%	645	$57K
97014		<1%	6,434	$55K
86780		<1%	5,437	$54K
J1439	Injection, ferric carboxymaltose, 1 mg	<1%	166	$54K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	11,081	$53K
95811		<1%	80	$52K
87086	Culture, bacterial; quantitative colony count, urine	<1%	28,848	$50K
80048	Basic metabolic panel (calcium, ionized)	<1%	40,515	$50K
76536		<1%	611	$44K
84439		<1%	7,660	$43K
82746		<1%	6,855	$41K
86703		<1%	7,220	$41K
93970		<1%	359	$40K
83550		<1%	9,778	$38K
99214	Doctor's office visit, returning patient (more involved)	<1%	2,598	$38K
83970		<1%	1,570	$38K
86803		<1%	6,016	$37K
95819		<1%	271	$36K
93798		<1%	732	$36K
97012		<1%	881	$35K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	1,014	$33K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	7,722	$32K
86235		<1%	714	$32K
97113		<1%	594	$32K
73221		<1%	181	$32K
66984	Extracapsular cataract removal with insertion of intraocular lens prosthesis	<1%	60	$31K
85027		<1%	11,912	$30K
83540		<1%	10,028	$29K
70553	Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences	<1%	100	$27K
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	<1%	28,399	$27K
72100		<1%	2,104	$25K
73030		<1%	2,680	$25K
70496		<1%	164	$25K
97112	Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination	<1%	2,343	$24K
86696		<1%	1,408	$23K
73130		<1%	2,302	$22K
86480		<1%	505	$22K
86141		<1%	3,914	$22K
84425		<1%	1,381	$21K
97116		<1%	1,739	$21K
97165		<1%	367	$21K
98968		<1%	449	$21K
84702		<1%	5,534	$20K
72110		<1%	313	$19K
72141		<1%	108	$19K
74018		<1%	1,579	$18K
87653		<1%	689	$17K
73630		<1%	2,891	$17K
0012A		<1%	540	$17K
98967		<1%	360	$17K
86038		<1%	2,862	$17K
0011A		<1%	707	$17K
82105		<1%	1,485	$17K
97530	Therapeutic activities, direct patient contact, each 15 minutes	<1%	2,044	$16K
73502		<1%	1,635	$16K
73560		<1%	693	$16K
84153		<1%	1,712	$16K
86695		<1%	1,377	$15K
H0035	Mental health partial hospitalization, treatment, less than 24 hours	<1%	123	$15K
49083		<1%	24	$14K
76642		<1%	274	$14K
77065	Tomosynthesis, mammo	<1%	167	$14K
87081		<1%	5,590	$14K
87340		<1%	3,659	$14K
86706		<1%	2,776	$14K
87186		<1%	6,060	$13K
87077		<1%	5,913	$13K
73610		<1%	2,658	$12K
81003		<1%	32,343	$12K
64493		<1%	16	$11K
82570		<1%	3,854	$11K
82784		<1%	2,505	$11K
73700		<1%	170	$11K
86334		<1%	2,102	$10K
29515		<1%	89	$10K
82043		<1%	3,144	$10K
70491		<1%	58	$10K
78815	Positron emission tomography (PET) for limited area imaging	<1%	12	$10K
88304		<1%	719	$10K
84403		<1%	585	$10K
73110		<1%	1,648	$10K
87147		<1%	5,279	$10K
83880		<1%	3,761	$10K
M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	<1%	29	$9K
86618		<1%	1,492	$9K
93880		<1%	131	$9K
83735		<1%	18,063	$9K
76817	Ultrasound, pregnant uterus, real time with image documentation, transvaginal	<1%	450	$9K
85610		<1%	13,535	$9K
83516		<1%	1,044	$8K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	2,830	$8K
86200		<1%	976	$8K
0001A		<1%	268	$8K
0002A		<1%	242	$8K
86762		<1%	2,424	$8K
85652		<1%	6,873	$8K
80076		<1%	7,949	$8K
86704		<1%	1,664	$7K
81001		<1%	17,670	$7K
73564		<1%	2,540	$7K
82550		<1%	3,867	$7K
76811	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed	<1%	29	$7K
Q3014	Telehealth originating site facility fee	<1%	841	$6K
87467		<1%	1,365	$6K
86140		<1%	2,785	$6K
83615		<1%	8,767	$6K
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	509	$6K
G0260	Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography	<1%	20	$6K
86787		<1%	2,000	$6K
82950		<1%	1,466	$6K
99442		<1%	482	$5K
84590		<1%	672	$5K
87088		<1%	2,882	$5K
86431		<1%	1,984	$5K
84165		<1%	2,007	$5K
97018		<1%	76	$5K
87070		<1%	1,574	$4K
84480		<1%	444	$4K
87205		<1%	2,538	$4K
83690		<1%	25,190	$4K
85730		<1%	5,282	$4K
64450		<1%	38	$3K
80050	General health panel	<1%	232	$3K
83001		<1%	240	$3K
29581		<1%	44	$3K
73080		<1%	524	$3K
86708		<1%	395	$3K
86753		<1%	571	$3K
71101		<1%	502	$3K
82565		<1%	1,961	$3K
82040		<1%	1,001	$3K
72070		<1%	115	$3K
96415		<1%	52	$3K
0031A		<1%	80	$3K
97535	Self-care/home management training, each 15 minutes	<1%	296	$3K
96417		<1%	44	$3K
M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	<1%	17	$2K
84146		<1%	167	$2K
74241		<1%	15	$2K
94664		<1%	71	$2K
73140		<1%	637	$2K
83519		<1%	136	$2K
J2272	Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg	<1%	2,420	$2K
84100		<1%	10,829	$2K
Q9969	Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose	<1%	337	$2K
82247		<1%	1,532	$2K
84550		<1%	1,491	$2K
74240		<1%	13	$2K
85045		<1%	2,574	$2K
84436		<1%	459	$2K
82652		<1%	59	$2K
83525		<1%	190	$2K
76700	Ultrasound, abdominal, real time with image documentation; complete	<1%	29	$2K
G0297	Low dose ct scan (ldct) for lung cancer screening	<1%	27	$2K
84450		<1%	2,705	$2K
86225		<1%	210	$2K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	1,093	$1K
77066	Tomosynthesis, mammo	<1%	16	$1K
85379		<1%	5,073	$1K
G0378	Hospital observation service, per hour	<1%	4,229	$1K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	1,874	$1K
83021		<1%	721	$1K
84703		<1%	2,602	$1K
83655		<1%	117	$1K
84145		<1%	3,627	$1K
J3490	Unclassified drugs	<1%	133,993	$1K
87102		<1%	150	$1K
84484		<1%	21,997	$1K
70498		<1%	200	$1K
84481		<1%	85	$1K
87506		<1%	13	$1K
94726		<1%	426	$993.62
83883		<1%	670	$976.61
84155		<1%	2,018	$971.29
84479		<1%	258	$946.64
82248		<1%	2,369	$836.23
96523		<1%	39	$828.73
84270		<1%	51	$788.88
83013		<1%	12	$771.84
86160		<1%	61	$745.55
J2469	Injection, palonosetron hcl, 25 mcg	<1%	349	$722.06
87040		<1%	3,383	$701.25
84075		<1%	2,019	$665.10
82803		<1%	2,782	$631.88
87493		<1%	39	$590.24
86666		<1%	117	$544.32
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	7,972	$533.25
82310		<1%	730	$528.58
85014		<1%	1,727	$475.51
86592		<1%	153	$459.91
80164		<1%	93	$437.36
86152		<1%	18	$424.68
99204	Doctor's office visit, new patient (more involved)	<1%	170	$410.60
83521		<1%	341	$370.80
12001		<1%	473	$369.64
87634		<1%	473	$356.79
84134		<1%	31	$348.00
84156		<1%	213	$334.88
72040		<1%	99	$322.34
82951		<1%	27	$319.54
90792	Psychiatric diagnostic evaluation with medical services	<1%	20	$312.64
88307		<1%	147	$311.74
86735		<1%	39	$286.58
86765		<1%	39	$283.13
86376		<1%	24	$275.77
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	677	$270.64
82948		<1%	16,591	$264.46
82150		<1%	100	$260.10
12002		<1%	211	$258.50
84460		<1%	2,699	$255.90
G8978	Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals	<1%	888	$246.91
85018		<1%	970	$246.34
70486		<1%	16	$245.22
99443		<1%	13	$229.56
86709		<1%	33	$215.00
82785		<1%	13	$204.49
87449		<1%	47	$199.59
73590		<1%	76	$197.17
29125		<1%	349	$192.22
90715		<1%	2,154	$189.23
85041		<1%	652	$176.00
81015		<1%	86	$171.10
83605		<1%	8,917	$161.96
84132		<1%	173	$143.56
87324		<1%	32	$142.60
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	2,415	$141.73
84144		<1%	27	$139.44
96376		<1%	6,226	$131.70
84520		<1%	1,107	$129.23
J7613	Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg	<1%	430	$117.98
J2785	Injection, regadenoson, 0.1 mg	<1%	1,085	$115.37
82140		<1%	84	$113.85
82533		<1%	15	$99.00
82232		<1%	130	$92.70
83014		<1%	12	$90.12
88313		<1%	3,009	$86.61
83721		<1%	16	$81.99
86850		<1%	7,483	$79.64
82330		<1%	82	$69.60
95251		<1%	359	$62.75
82977		<1%	33	$61.40
82553		<1%	306	$52.90
J1644	Injection, heparin sodium, per 1000 units	<1%	3,782	$41.27
J0689	Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg	<1%	121	$39.92
90686		<1%	21	$38.06
J2060	Injection, lorazepam, 2 mg	<1%	4,866	$30.93
86308		<1%	29	$29.64
94727		<1%	2,281	$28.02
J0134	Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg	<1%	299	$25.00
J0665	Injection, bupivicaine, not otherwise specified, 0.5 mg	<1%	1,308	$14.52
A9270	Non-covered item or service	<1%	15,913	$13.51
87807		<1%	121	$11.45
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	22,182	$10.17
80051		<1%	23	$9.43
J2270	Injection, morphine sulfate, up to 10 mg	<1%	8,198	$9.41
J7620	Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme	<1%	2,337	$7.37
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	15,819	$5.33
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	17,664	$5.07
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	3,946	$4.80
84295		<1%	51	$4.59
82009		<1%	182	$4.31
82962		<1%	813	$4.29
G8979	Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	<1%	1,025	$4.09
J2765	Injection, metoclopramide hcl, up to 10 mg	<1%	4,505	$2.40
J1630	Injection, haloperidol, up to 5 mg	<1%	2,026	$1.95
J0690	Injection, cefazolin sodium, 500 mg	<1%	6,518	$1.94
G0283	Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care	<1%	66	$1.87
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	6,594	$1.81
J1170	Injection, hydromorphone, up to 4 mg	<1%	5,694	$1.00
G8980	Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting	<1%	103	$0.27
G8988	Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	<1%	62	$0.17
G8987	Self care functional limitation, current status, at therapy episode outset and at reporting intervals	<1%	45	$0.14
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	3,991	$0.08
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	0%	2,187	$0.00
76813		0%	975	$0.00
C1776	Joint device (implantable)	0%	45	$0.00
J0171	Injection, adrenalin, epinephrine, 0.1 mg	0%	1,396	$0.00
94729		0%	2,703	$0.00
J2550	Injection, promethazine hcl, up to 50 mg	0%	286	$0.00
A9575	Injection, gadoterate meglumine, 0.1 ml	0%	1,690	$0.00
J3475	Injection, magnesium sulfate, per 500 mg	0%	988	$0.00
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	0%	1,388	$0.00
Q0163	Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen	0%	1,401	$0.00
77002		0%	88	$0.00
G1004	Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program	0%	687	$0.00
C1713	Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	0%	850	$0.00
J0780	Injection, prochlorperazine, up to 10 mg	0%	586	$0.00
76942		0%	312	$0.00
Q9957	Injection, perflutren lipid microspheres, per ml	0%	743	$0.00
J3370	Injection, vancomycin hcl, 500 mg	0%	122	$0.00
93356		0%	710	$0.00
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	0%	12	$0.00
C1887	Catheter, guiding (may include infusion/perfusion capability)	0%	234	$0.00
12011		0%	45	$0.00
91300		0%	494	$0.00
J1650	Injection, enoxaparin sodium, 10 mg	0%	712	$0.00
J2919	Injection, methylprednisolone sodium succinate, 5 mg	0%	337	$0.00
J1453	Injection, fosaprepitant, 1 mg	0%	41	$0.00
J1171	Injection, hydromorphone, 0.1 mg	0%	168	$0.00
C9113	Injection, pantoprazole sodium, per vial	0%	412	$0.00
C1874	Stent, coated/covered, with delivery system	0%	16	$0.00
J1596	Injection, glycopyrrolate, 0.1 mg	0%	15	$0.00
J2250	Injection, midazolam hydrochloride, per 1 mg	0%	2,424	$0.00
C1769	Guide wire	0%	149	$0.00
J1040	Injection, methylprednisolone acetate, 80 mg	0%	431	$0.00
J2704	Injection, propofol, 10 mg	0%	8,350	$0.00
J3010	Injection, fentanyl citrate, 0.1 mg	0%	5,777	$0.00
J7999	Compounded drug, not otherwise classified	0%	32	$0.00
A9500	Technetium tc-99m sestamibi, diagnostic, per study dose	0%	1,733	$0.00
J2371	Injection, phenylephrine hydrochloride, 20 micrograms	0%	384	$0.00
J1642	Injection, heparin sodium, (heparin lock flush), per 10 units	0%	1,827	$0.00
J3420	Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg	0%	806	$0.00
88341		0%	503	$0.00
J1030	Injection, methylprednisolone acetate, 40 mg	0%	335	$0.00
J2471	Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg	0%	47	$0.00
96368		0%	68	$0.00
G0471	Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha)	0%	1,109	$0.00
J2370	Injection, phenylephrine hcl, up to 1 ml	0%	535	$0.00
J7609	Albuterol, inhalation solution, compounded product, administered through dme, unit dose, 1 mg	0%	225	$0.00
91303		0%	66	$0.00
C1889	Implantable/insertable device, not otherwise classified	0%	298	$0.00
J2543	Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams)	0%	126	$0.00
J3480	Injection, potassium chloride, per 2 meq	0%	72	$0.00
J2795	Injection, ropivacaine hydrochloride, 1 mg	0%	193	$0.00
J2003	Injection, lidocaine hydrochloride, 1 mg	0%	175	$0.00
91301		0%	1,142	$0.00
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	0%	128	$0.00
82435		0%	51	$0.00
J2001	Injection, lidocaine hcl for intravenous infusion, 10 mg	0%	122	$0.00
J0131	Injection, acetaminophen, not otherwise specified,10 mg	0%	202	$0.00
86880		0%	77	$0.00
64494		0%	16	$0.00
76870		0%	18	$0.00
J1010	Injection, methylprednisolone acetate, 1 mg	0%	28	$0.00
64415		0%	14	$0.00
G0108	Diabetes outpatient self-management training services, individual, per 30 minutes	0%	14	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBARWIS, KURT (PRESIDENT AND CEO)